CN105753992A - Pseudomonas aeruginosa recombinant protein Vac11 as well as preparation method and application - Google Patents

Pseudomonas aeruginosa recombinant protein Vac11 as well as preparation method and application Download PDF

Info

Publication number
CN105753992A
CN105753992A CN201610117642.9A CN201610117642A CN105753992A CN 105753992 A CN105753992 A CN 105753992A CN 201610117642 A CN201610117642 A CN 201610117642A CN 105753992 A CN105753992 A CN 105753992A
Authority
CN
China
Prior art keywords
pseudomonas aeruginosa
vac11
recombiant protein
expression vector
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610117642.9A
Other languages
Chinese (zh)
Other versions
CN105753992B (en
Inventor
章金勇
顾江
邹全明
杨峰
杨茜
赵莉群
彭六生
吴翼
王逸麟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Third Military Medical University TMMU
Chengdu Olymvax Biopharmaceuticals Inc
Original Assignee
Third Military Medical University TMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Third Military Medical University TMMU filed Critical Third Military Medical University TMMU
Priority to CN201610117642.9A priority Critical patent/CN105753992B/en
Publication of CN105753992A publication Critical patent/CN105753992A/en
Application granted granted Critical
Publication of CN105753992B publication Critical patent/CN105753992B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a pseudomonas aeruginosa recombinant protein Vac11 as well as a preparation method and an application. Animal tests prove that the recombinant protein can effectively stimulate organisms to carry out higher humoral immune response and give play to good immunoprotection effects, thus being beneficial to prevention, diagnosis and treatment of pseudomonas aeruginosa. The recombinant protein prepared by adopting the method provided by the invention has high expression quantity and is convenient to separate and purify.

Description

Pseudomonas aeruginosa recombiant protein Vac11 and preparation method and application
Technical field
The invention belongs to biotechnological pharmaceutics field, be specifically related to a kind of Pseudomonas aeruginosa recombiant protein Vac11 (AmpDh3), the invention further relates to the preparation method of this recombiant protein and application thereof.
Background technology
Pseudomonas aeruginosa (Pseudomonasaeruginosa, PA) it is commonly called as bacillus pyocyaneus, for the Rhodopseudomonas in non-zymocyte, it is distributed widely in nature, normal human skin, intestinal, respiratory tract, also ubiquity in hospital ward and medical apparatus and instruments, is one of most commonly seen clinically conditioned pathogen.At present in the world, this bacterium has become ICU ward, burn, War injury infection, one of ventilator-associated pneumonia (VAP) pathogen that separation rate is the highest.PA infects and can occur at any position of human body and tissue, such as burn or wound site, middle ear, cornea, urethra and respiratory tract etc., it is possible to causing the systemic infection such as endocarditis, gastroenteritis, pneumonia even septicemia, systemic infection mortality rate is more than 20%.
Additionally, due to reasons such as antibiotic abuses, the resistance problems of PA highlights gradually, occurs in that general tolerant Pseudomonas aeruginosa (PDR-PA) and multi-resistant Pseudomonas aeruginosa (MDR-PA), and the separation rate of drug resistance PA rises year by year.China's continuous monitoring materials of CHINET2005--2012 shows, the resistant rate of Common Antibiotics is maintained at higher level by PA, but slightly on a declining curve.Annual resistant rate respectively 31.0%, 42.8%, 35.8%, 30.5%, 30.5%, 30.8%, 29.1% and 29.1% such as imipenum, to the annual resistant rate of meropenem respectively 32.0%, 34.1%, 28.5%, 24.5%, 25.2%, 25.8%, 25.0% and 27.1%, but wherein general drug resistance (PDR-PA) bacterial strain quantity significantly increases, respectively reached 1.8% and 1.5% (pneumonia caused by Pseudomonas aeruginosa infected specialist's common recognition at 2011 and 2012, China's tuberculosis and breathing magazine, volume 1 phase January 37 in 2014).Constantly soaring due to PA high infection rate clinically and resistant rate, finds new " non-antibiotic therapy " extremely urgent, starts with from immunology angle, develop the selection that safely and effectively vaccine becomes ideal.
Genetic engineering subunit vaccine is by engineered means, and by the gene clone of the virulence factor of pathogen or its mutant protein expression vector extremely, recon is expressed on a large scale in engineering bacteria, prepares into genetic engineering subunit vaccine after purification.This vaccine has that technique is simple, cost is low, workable etc. a little, it has also become the important directions of vaccine research and development.Research and development recombinant vaccine it is crucial that screen good protective antigen molecule.
AmpDh3 is the typical zinc protease of Pseudomonas aeruginosa, and it is positioned at the week slurry gap of antibacterial, plays a significant role (LeeM etc., JAmChemSoc.2013) in the formation and reconstruct (re-modeling) process of bacteria cell wall.Additionally, the disappearance of AmpDh3 gene can cause that the virulence of Pseudomonas aeruginosa bacteria is decreased obviously (MoyaB waits AntimicrobAgentsChemother.2008).In view of AmpDh3 important function in Pseudomonas aeruginosa physiology and pathogenic course, it can as the important candidate antigens of recombination engineering subunit vaccine.
Summary of the invention
It is an object of the invention to provide a kind of Pseudomonas aeruginosa recombiant protein Vac11 and preparation method and application; described recombiant protein proves through animal experiment; higher humoral immunoresponse(HI) and good immanoprotection action can be produced by effective stimulus body, be conducive to the prevention of Pseudomonas aeruginosa, diagnose and treat.Adopting recombiant protein prepared by illustrated method, expression is high, be easy to separation purification.
For achieving the above object, the present invention provides following technical scheme:
Pseudomonas aeruginosa recombiant protein Vac11, comprises the typical zinc protease of Pseudomonas aeruginosa, and the nucleotides sequence of this recombiant protein is classified as SEQIDNO:1, and aminoacid sequence is SEQIDNO:2.
A kind of expression vector, comprises the nucleotide sequence encoding above-mentioned recombiant protein.
Described expression vector can be connected, by skeleton plasmid, the nucleotide sequence encoding above-mentioned recombiant protein and be formed with modifying；Preferably, described skeleton plasmid is selected from pGex serial carrier, pET serial carrier or pQE serial carrier, it is preferred to pGex-6P-2.
Comprise the Host Strains of above-mentioned expression vector.
Described Host Strains one in E.colistrain XL1 blue, BL21 or HMS174 bacterial strain, it is preferred to E.colistrain XL1 blue bacterial strain.
The preparation method of Pseudomonas aeruginosa recombiant protein Vac11, has following steps:
1) nucleotide sequence according to coding Pseudomonas aeruginosa recombinant subunit vaccine Vac11 recombiant protein is synthesized into or designs forward primer and reverse primer by full genome, does template pcr amplification with Pseudomonas aeruginosa full-length genome and obtains Pseudomonas aeruginosa recombinant subunit vaccine Vac11 genes of interest fragment；
2) by step 1) gained gene fragment clone to expression vector, then convert to Host Strains；
3) Host Strains after Induction Transformation expresses Vac11 recombiant protein.
4) purification of Vac11 recombiant protein.
Step 1) described in forward primer and the nucleotide sequence of reverse primer such as shown in SEQIDNO:3 and SEQIDNO:4.
Above-mentioned recombiant protein is used for the application diagnosing, prevent or treating in the medicine of Pseudomonas aeruginosa in preparation.
Good technical scheme is described medicine is the test kit for diagnosing Pseudomonas aeruginosa.
Good technical scheme is described medicine is the subunit vaccine for preventing or treat Pseudomonas aeruginosa.
The present invention adopts this recombination fusion protein of technique for gene engineering clonal expression, and expression is high, it is simple to separation purification, and highly effective and safe.Vac11 recombiant protein can directly be inoculated with the use of, it is adaptable to injecting immune with adjuvant (such as aluminum hydroxide adjuvant, Aluminium phosphate adjuvant, monostearate aluminium adjuvant, MF59, complete Freund's adjuvant, incomplete Freund's adjuvant, mycobacteria bacillus calmette-guerin vaccine adjuvant etc.).
Owing to have employed technique scheme, present invention have the advantage that:
1) Vac11 expression of recombinant proteins plasmid abduction delivering in prokaryotic expression system-escherichia coli；
2), when selecting pGEX carrier families, Vac11 recombiant protein is with fusion protein form expression；Expression vector is connected to the glutathione-S-transferase (GST) that molecular weight is 26kDa, expressed fusion protein just contains a GST label, this label just becomes the labelling of protein purification, the albumen after purification makes the addition that purification condition is gentle, step is simple, do not need denaturant, thus can keep its space conformation and immunogenicity to greatest extent；The Vac11 recombiant protein purity being purified is more than 95%；
3) Vac11 recombiant protein can produce specific antibody and have immune protective effect by induced animal.
Utilizing subunit vaccine prepared by Vac11 recombiant protein of the present invention can carry out immunity inoculation by subcutaneous (muscle) injecting pathway, excitating organism produces high titre IgG antibody.And animal experiment proves that, described genetic engineering recombinant protein vaccine has the good anti-PA immune protective effect infected.Studying for further combined vaccine and many subunits fusion bacterin and lay the first stone, development and application for preventing and treating vaccine and diagnostic kit simultaneously has important effect.
Accompanying drawing explanation
Fig. 1 is the pcr amplification result of Vac11 genetic fragment, wherein swimming lane 1: nucleic acid (DNA) molecular weight standard (Marker), from top to bottom size be respectively as follows: 4500,3000,2000,1200,800,500,200bp；；Swimming lane 2&3: genes of interest fragment Vac11 (～750bp)；
Fig. 2 is the double digestion qualification result of recombiant plasmid pGex-6P-2-Vac11, wherein, swimming lane 1: nucleic acid (DNA) molecular weight standard (Marker), from top to bottom size be respectively as follows: 4500,3000,2000,1200,800,500,200bp；Swimming lane 2: recombinant expression plasmid pGEX-6p-2-Vac11 qualification result after enzyme action, the fragment separated after enzyme action is about 4000bp and about 750bp；
Fig. 3 is that albumen Vac11 induces qualification result, wherein, and swimming lane 1: Protein Marker (Marker), size is respectively as follows: 170Kd, 130Kd, 100Kd, 70Kd, 55Kd, 40Kd, 35Kd, 25Kd, 15Kd, 10Kd from top to bottom；Swimming lane 2: the GST filler of the ultrasonic supernatant that zygotic induction is expressed；Swimming lane 3～5: the supernatant after PP enzyme enzyme action；Swimming lane 6: the GST filler after PP enzyme enzyme action；
Fig. 4 is the albumen Vac11SDS-PAGE electrophoresis result after purification, wherein, swimming lane 1: Protein Marker (Marker), size is respectively as follows: 170Kd, 130Kd, 100Kd, 70Kd, 55Kd, 40Kd, 35Kd, 25Kd, 15Kd, 10Kd from top to bottom；Swimming lane 2: the Vac11 albumen of purification.
Detailed description of the invention
In order to make the purpose of the present invention, technical scheme and advantage clearly understand, below in conjunction with drawings and Examples, the present invention is described in more detail.Should be appreciated that the specific embodiment herein saying description is only in order to explain the present invention, is not intended to limit the present invention.
Bacterial strain is as follows with various reagent:
1. pseudomonas aeruginosa strains
Pseudomonas aeruginosa international standard strain PA01 by U.S. ATCC provide (BAA-47TM)；
2. (preserving number is CCTCCNO:M2015730 to P. aeruginosa clinical strain XN-1, and Classification And Nomenclature is: Pseudomonas aeruginosa XN-1, Latin title: PseudomonasaeruginosaXN-1, preservation time: 2015.12.9；Depositary institution: China typical culture collection center (CCTCC)；Preservation place: Bayi Road Luo Jia Shan, Wuchang District, Wuhan City, Hubei Province)；
3. reagent
Plasmid pGEX-6p-2 is purchased from GEHealthcareLifeSciences company, and applicant preserves；
Coli strain XL-1blue is purchased from Chao Yan bio tech ltd, Shanghai, and applicant preserves；
PrimeSTARHSDNAPolymerase, DNAMarker, restricted enzyme BamHI and EcoRI, albumen Marker are Dalian TakaRa Products；
It is U.S.'s Omega Products that plasmid extraction kit and gel reclaim test kit；
It is sky root Products that bacterial genomes extracts test kit, ultra-thin recovery test kit and nitrite ion；
T4DNALigase is Fermentas Products；
Glutathione-Sepharose GlutathioneSepharose4B is U.S.'s GEHealthcare Products.
Embodiment 1The clone of Vac11 gene and the structure of recombiant plasmid pGEX-6P-2-Vac11
1. the AmpDh3 full length protein gene order according to Pseudomonas aeruginosa PA01, applying biological information software carries out structural analysis, it is determined that need the Vac11 genes of interest fragment of amplification.
2. according to analyzing result, adopting PCR method from PA01 genome amplification AmpDh3 genes of interest fragment, amplification step is as follows:
1) design PCR primer is as follows, respectively SEQIDNO:3-4 (underscore shows restriction enzyme site base sequence)
2) the pseudomonas aeruginosa strains PA01 taking out preservation in-80 DEG C of freezers coats on LB solid medium, in 37 DEG C of overnight incubation, picking list colony inoculation is cultivated 8 hours in LB liquid bulk culture medium again, with reference to bacterial genomes extraction agent box extracting PA01 genome.
3) with PA01 complete genome DNA for template PCR amplifications AmpDh3 full-length gene
PCR system:
Template (239.2ng/ μ l) 2.5μl
Vac11-F(50μM) 1.0μl
Vac11-R(50μM) 1.0μl
PrimeSTAR enzyme 2.5μl
dNTP 2.0μl
Buffer 15.0μl
Sterilizing distilled water 26.0μl
Cumulative volume 50.0μl
98 DEG C of denaturation 5min of pcr amplification reaction condition, 98 DEG C of degeneration 30s, 55 DEG C of annealing 30s, 72 DEG C extend 90s, 30 circulations, 72 DEG C of fully extended 6min.Using the agarose gel detection pcr amplification result of 1% after completion of the reaction, pcr amplification result is shown in Figure 1.
4) use gel to reclaim test kit and reclaim AmpDh3PCR product.
The qualification of 3.PCR product and clone, step is as follows:
1) BamHI and EcoRI enzyme action pGEX-6P-2 plasmid and AmpDh3PCR product
Endonuclease reaction system:
37 DEG C of enzyme action 2h.
2) ultra-thin recovery test kit is used to reclaim pGEX-6P-2 plasmid and the PCR primer through BamHI and EcoRI enzyme action.
3) connect and convert
Measure AmpDh3 enzyme action by ultraviolet spectrophotometer and reclaim product nucleic acid concentration: 21ng/ μ l, pGEX-6P-2 enzyme action reclaims product nucleic acid concentration: 60ng/ μ l.
Coupled reaction system:
Project Volume
Coupled reaction liquid Soultion I 5.0μl
AmpDh3 enzyme action reclaims product 4.5μl
PGEX-6P-2 enzyme action reclaims product 0.5μl
Mixing, 16 DEG C connect 2h.
4) taking 3 pipe escherichia coli XL1blue competent cells from-80 DEG C of refrigerators, the first pipe adds pGEX-6P-2 plasmid, makes positive control；Second pipe adds DNA and connects product；3rd pipe is not added with foreign DNA, makes negative control.Ice bath 50min, thermal shock 90s in 42 DEG C of metal baths, rapid ice bath 2min.Add 600ulLB blank cultures, mixing, be placed in 37 DEG C of shaking tables 220rp jolting 1h.
Each pipe, with the centrifugal 3min. of 5000rpm room temperature, discards 300ul supernatant more resuspended thalline, takes 200 μ l and coat Amp resistance LB flat board.Flat-plate inverted is placed in 37 DEG C of incubators and cultivates 24h.
5) screening of pGEX-6p-2-Vac11 positive recombiant plasmid, qualification
1. negative control plates does not have bacterium colony to occur；Positive control flat board covers with bacterium colony, illustrates that competent cell makes correct, credible result.Picking converts and separates good bacterium colony on flat board, is inoculated in Amp resistance LB culture medium, and 37 DEG C of shaken cultivation are overnight；
2. plasmid extraction: carry out with reference to plasmid extraction kit description；
3. plasmid DNA carries out BamHI and EcoRI double digestion；
Double digestion reaction system:
Project Volume
BamH I 0.5μl
Not I 0.5μl
10×K Buffer 0.5μl
0.1%BSA 1.0μl
Recombiant plasmid 8.0μl
37 DEG C of enzyme action 2h；
4. the agarose gel electrophoresis detection double digestion result of 1%, result is Fig. 2 such as, it is seen that swimming lane 2 sample is the pGEX-6p-2-Vac11 recombiant plasmid successfully constructed；
5. pGEX-6p-2-Vac11 recombiant plasmid is sent to the order-checking of the handsome company in Shanghai, and sequencing result is than GeneBank sequence information comparison, found that the consecutive nucleotides sequence of the two is identical.
Embodiment 2: recombination fusion protein Vac11 is the qualification of abduction delivering, purification and expression-form in prokaryotic expression system-escherichia coli
1.Vac11 abduction delivering
Take in the LB culture medium of pGEX-6P-2-Vac11/XL-1blue bacterium solution 100 μ L addition 10mLAmp+ resistance of incubated overnight, 180rpm37 DEG C of incubated overnight, take respectively incubated overnight bacterium solution 400 μ L add 20mLAmp+ resistance LB culture medium in (remaining bacterium solution is saved in 4 DEG C of refrigerators standby), cultivate 2～3h for 37 DEG C, rotating speed 200rpm, re-activation to OD600 be 0.8-1.0 time, add IPTG4 μ L, make its final concentration of 200 μMs, then be placed in 30 DEG C of abduction delivering 3h of shaking table abduction delivering.
2) bacterium solution after abduction delivering is taken out, with the centrifugal 5min of 12000rpm, supernatant discarded, add 1mLlysisbuffer (20mMPB, pH7.2,250mMNacl) mixing, ultrasonic degradation 3min (ultrasonic 6 times 30s/ time), 4 DEG C of centrifugal 15min of 14000rpm, cleer and peaceful precipitation in separation again.
2. process supernatant
Taking GlutathioneSepharose4B20 μ l, after washing 3 times with PBS, added in GlutathioneSepharose4B by ready supernatant, room temperature is in conjunction with 1h., after the centrifugal 3min of 14000rpm, to use PBS-0.25% polysorbas20 to wash 2 times at 4 DEG C, PBS washs once.GlutathioneSepharose4B after combining adds 20 μ L2 × protein loading buffer, boils the centrifugal 3min of 5min, 14000rpm.
3. process precipitation
Precipitation adds the 500 resuspended thalline of μ LPBS, takes the 80 resuspended bacterium solution of μ L and add 20 μ L5 × protein loading buffer, boil the centrifugal 3min of 5min, 14000rpm.
4.SDS-PAGE electrophoresis
Pouring in glue version by 5% concentration glue, glue laminated put down adding distilled water, room temperature places 30min makes it solidify, and is fallen by the distilled water on upper strata dry, then pours into 10% separation gel, plugs comb immediately, and it is standby that room temperature placement 30min makes it solidify.The upper cleer and peaceful precipitation handled well is taken respectively 10 μ L loadings, carries out SDS-PAGE electrophoresis.Voltage elder generation 80v electrophoresis 30min, it is adjusted to 180v again, after electrophoresis 1～2h, glue is taken out, it is placed in coomassie brilliant blue staining liquid vibration dyeing, after being placed in destaining solution vibration decolouring again, observed result under imaging system, PGEX-6P-2-Vac11/XL-1blue is soluble protein (Fig. 3) at 30 DEG C.
The preparation of embodiment 3:Vac11 antigen
1. amplification culture obtains albumen
nullThe standby pGEX-6P-2-Vac11/XL-1blue bacterium solution 400 μ L in 4 DEG C of refrigerators of existence that goes bail for joins in the 20mL LB culture medium containing Amp resistance and once activates，After 200rpm37 DEG C of cultivation 5～6h，Take the 8mL bacterium solution once activated to join in the 400mL LB culture medium containing Amp resistance and carry out re-activation，When 37 DEG C of cultivation 3～4h to OD600 are 1.0，Add 80 μ LIPTG (final concentration of 200 μMs) be placed in 16 DEG C of shaking tables overnight induction after，The centrifugal 15min of 12000rpm collects thalline,After adding 20mLlysisbuffer (with embodiment 2) resuspended thalline again，Bacterium solution is carried out ultrasonic degradation 3min (200V)，Collect supernatant and 800 μ L to process for GlutathioneSepharose4B (GE company) gel beads (beads) combination in conjunction with gst fusion protein；Carry out PAGE gel electrophoresis again.
2. use enzymatic cleavage methods, destination protein and GST label are separated, obtains Vac11 destination protein
800 μ LPBS and 120 μ LPreScissionprotease (PP enzymes are added in the remainder about 800 protein-bonded GlutathioneSepharose4B of μ L, GE company), after room temperature vertical rotary enzyme action 5h, after centrifugal absorption supernatant, wash 3 times with 800 μ LPBS respectively, after taking 10 μ L sample degenerative treatments after each, loading 5 μ L carries out protein electrophoresis (method is ibid), observed result under in phase system, the Vac11 molecular weight of albumen that enzyme action gets off is at～30kDa, it is consistent with expection molecular weight of albumen size, sees Fig. 4.
Embodiment 4: the structure of charrin disease Pneumonia Mice model
1. Pseudomonas aeruginosa bacterium solution preparation
Take frozen P. aeruginosa clinical strain XN-1 (CCTCCM2015730), adopt the recovery of LB nutrient agar panel, 37 DEG C of aerobic overnight incubation.The single colony inoculation 20mLLB fluid medium of picking, after 37 DEG C of aerobic 180rpm shaken cultivation 15h, takes 0.2mL and is inoculated in 20mLLB fluid medium, 37 DEG C of aerobic 230rpm shaken cultivation 6h.The centrifugal thalline of collecting of 6000g, with normal saline resuspension thalline after brine twice.Adopt the OD of spectrophotometric determination bacterium solution600Value, and according to 1OD=6.0 × 109CFU/ml is converted into bacterial concentration.
2. the foundation of mouse anesthesia and collunarium scheme
In the infection experiment of pseudomonas aeruginosa pneumonia model, for ensureing being smoothed out of collunarium process, initially with isoflurane by mouse anesthesia.Anesthesia: carry out sucking induced anesthesia for delivery vehicles with the isoflurane of 5% concentration with oxygen, enters after surgery stage of deep narcosis until mice, and the concentration with 3% maintains anesthesia, and this mode can reach good anaesthetic effect.The control of collunarium dosage is the guarantee of model stability, in order to better control collunarium dosage, prevent bacterium solution in collunarium process from entering oral cavity and producing bubble simultaneously, take following measures: (1) has a physiologic radian due to nasopharynx part, head is faced upward more severe, nasal drop is more easily accessible oral cavity, so collunarium process small mouse head is lain on the back, amplitude not can exceed that the physiologic radian of nasopharynx part；(2) drip medicine along lateral wall of nasal cavity, reduce the generation of bubble in collunarium process as far as possible；(3) get hold of the rhythm of collunarium, drip 4 below μ L amounts in the moment that mice air-breathing starts；(4) in the present embodiment, collunarium amount is 20 μ L, and single-nostril one-time continuous instills.
3. the determination of infective dose
The PAXN-1 bacterium solution that embodiment 1 is obtained by normal saline is adopted to regulate to five kinds of variable concentrations, laboratory animal female BAl BIc/c mice is randomly divided into 5 groups, infect with adopting the mode of collunarium after isoflurane anesthesia mice, every mouse infection dosage is 20 μ L, adopts same dose of normal saline (NS) as blank.Packet and the infection conditions of animal are as shown in table 1.Infection terminate after every 1 day observe dead mouse situation, the observation cycle is 7 days, the observation period terminate after residue animal with CO2Inhalation euthanasia.
Table 1: the determination of pseudomonas aeruginosa pneumonia model infective dose
Group Collunarium Dosage (CFU) Quantity Concentration (CFU/ml) Infusion volume (μ l)
1 PAXN-1 6.00×108 10 3.00×1010 20
2 PAXN-1 3.00×108 10 1.50×1010 20
3 PAXN-1 1.50×108 10 7.50×109 20
4 PAXN-1 7.50×107 10 3.75×109 20
5 PAXN-1 3.75×107 10 1.88×109 20
6 Normal saline - 10 - 20
Adopt variable concentrations (2 times of gradient dilutions) pseudomonas aeruginosa strains PAXN-1 infect BALB/c mouse time, through the observation of 7 days, result as shown in Figure 1: infective dose is 1.5 × 108During CFU, mouse death rate is 40%, and infective dose is 3.0 × 108During CFU, mouse death rate is 80%, and infective dose reaches 6.0 × 108Mouse death rate 100% during CFU.The preferred dose determining mouse infection is 3.0 × 108CFU。
Embodiment 5: the immunity of animal
1) first immunisation, dilutes Vac11 antigen with PBS, adds the Al (OH) that concentration is 1mg/mL3；With No. 5 half mould syringe needles, bilateral inguinal, vola and dorsal sc are to an injection, and every BALB/C mice injection volume is 100 μ L, and arranges positive controls, negative control group and blank group；
2) second time immunity, carries out second time immunity on the 7th day, and ibid, injection volume proteantigen amount is the 1/2 of first immunisation to immune component, and immunization route is ibid；
3) third time immunity, carries out third time immunity on the 14th day, and ibid, injection volume proteantigen amount is identical with second time immunity, and immunization route is ibid for immune component；
Embodiment 6: the detection of antibody
After third time immunity the 7th and 14 day, gather the blood of BALB/C mice, detect after mouse immune with ELISA, IgG, IgG1, IgG2aHumoral response level.
1. prepare liquid
1) preparation of liquid it is coated: weigh Na2CO31.6g, NaHCO32.9g, is dissolved in 1LddH2O, is adjusted to 9.6 with PH meter by pH；
2) preparation of confining liquid: 1g Ox blood serum V, is dissolved in 100mL antibody diluent (1:100)；
3) preparation of antibody diluent: phosphate is dissolved in 1LddH2O, adds 500 μ LTween20, then with PH meter, pH is adjusted to 7.4；
4) preparation of cleaning mixture: synantibody diluent
5) nitrite ion (TMB), for sky root Products；
6) stop buffer (2MH2SO4) preparation: 22.2mL concentrated sulphuric acid is poured into 177.8mLddH2In O.
2.ELISA detects the antibody titer that Vac11 recombiant protein immune mouse produces
1) be coated liquid by after purification Vac11 recombiant protein dilute be: 1ug/mL, 5ug/mL, 10ug/mL；
2) it is coated: recombiant protein diluent adds ELISA Plate, 100 μ L/ holes, and 4 DEG C are overnight washed 3 times with cleaning mixture afterwards, wrap with preservative film, be placed in 4 DEG C of refrigerators standby after sky is dry；
3) close: ELISA Plate adds confining liquid 200 μ L/ hole, is placed in 37 DEG C of incubators 2 hours, washs 3 times；
4) serum is carried out the doubling dilutions such as 1:100,1:500,1:1000,1:2000,1:4000,1:8000；
5) take the ELISA Plate closed, be sequentially added into dilute serum, 100 μ L/ holes, it is placed in 37 DEG C of incubator 1h, washs 3 times, empty dry；
6) by adding the goat anti-mouse igg of HRP labelling, IgG1, IgG2a antibody preservation liquid, dilute 1:5000, make antibody working solution；
7) add dilution antibody working solution, 100 μ L/ holes, be placed in 37 DEG C of incubator 40min, wash three times, empty dry；
8) substrate nitrite ion (TMB) 100 μ L/ hole is added, room temperature lucifuge reaction 5min；
9) stop buffer (2MH is added2SO4), it is immediately placed in microplate reader and measures OD value with 450nm wavelength place；
10) result judges: ASampleANegativeValue 2.1 is positive (negative control is that before mouse immune, serum 1:1000 times dilutes).
Result: the antibody titer that detection Vac11 proteantigen immune mouse produces reaches 1:1024000；After immunity, the antibody positive rate of the 7th day reaches 100%, illustrates that the Vac11 recombiant protein that the present invention builds can make to produce in immune mouse body antibody.
The counteracting toxic substances protection of embodiment 7:Vac11 recombiant protein animal immune is evaluated
After Vac11 final immunization 10～14 days, adopt the method identical with embodiment 3, by preparation PAXN-1 bacterium solution and regulate concentration to 1.5 × 10 with normal saline10CFU/mL, with adopting the mode of collunarium to infect after isoflurane anesthesia mice, every mouse infection amount is 20 μ L, adopts same dose of normal saline (NS) as blank.Infection terminate after every 1 day observe dead mouse situation, the observation cycle is 7 days, the observation period terminate after residue animal with CO2Inhalation euthanasia.Add up the survival rate of each group of mice.Result is shown in table 2.
Counteracting toxic substances protected effect after table 2Vac11 recombiant protein immune mouse
Table 2 shows: the average immune protective rate of negative control group and blank group respectively 20% and 25%, recombination fusion protein Vac11 adds Al (OH)3The average immune protective rate of adjuvant group is 70%.Therefore, the Vac11 recombiant protein of the present invention has good immunogenicity, it is possible to induction body produces immunne response, and can the infection of PAXN-1 be played a protective role, it is possible to is aided with aluminium adjuvant and prepares subunit vaccine for preventing the infection of Pseudomonas aeruginosa.
Pass through above example, those skilled in the art utilize ordinary skill knowledge can apply the recombiant protein prepared by the present invention and other related reagents apparently, such as it is coated reagent, detection antibody, developer, terminator etc. and prepares related kit, such as detection kit, for whether diagnosis is infected Pseudomonas aeruginosa, is determined prognosis etc..
Vac11 recombiant protein of the present invention can be used for other any applicable purposes by those skilled in the art.
The foregoing is only presently preferred embodiments of the present invention, be not used for limiting the practical range of the present invention；If without departing from the spirit and scope of the present invention, the present invention is modified or equivalent replacement, all should be encompassed in the middle of the protection domain of the claims in the present invention.

Claims (10)

1. a recombiant protein, it is characterised in that: this recombiant protein comprises Pseudomonas aeruginosa zinc protease, and the nucleotides sequence of described recombiant protein is classified as SEQIDNO:1, and aminoacid sequence is SEQIDNO:2.
2. an expression vector, it is characterised in that: comprise the nucleotide sequence of recombiant protein described in coding claim 1.
3. expression vector according to claim 2, it is characterised in that: described expression vector can be connected, by skeleton plasmid, the nucleotide sequence encoding above-mentioned recombiant protein and be formed with modifying；Preferably, described skeleton plasmid is selected from pGex serial carrier, pET serial carrier or pQE serial carrier, it is preferred to pGex-6P-2.
4. comprise the Host Strains of the arbitrary described expression vector of claim 2-3.
5. Host Strains according to claim 4, it is characterised in that: described Host Strains one in E.colistrain XL1 blue, BL21 or HMS174 bacterial strain, it is preferred to E.colistrain XL1 blue bacterial strain.
6. the preparation method of the recombiant protein described in claim 1, it is characterised in that including:
1) nucleotide sequence according to coding Pseudomonas aeruginosa recombinant subunit vaccine Vac11 recombiant protein is synthesized into or designs forward primer and reverse primer, does template pcr amplification with Pseudomonas aeruginosa full-length genome and obtains Pseudomonas aeruginosa recombinant subunit vaccine Vac11 genes of interest fragment；
2) by step 1) gained gene fragment clone to expression vector, then convert to Host Strains；
3) Host Strains after Induction Transformation expresses Vac11 recombiant protein.
4) purification of Vac11 recombiant protein.
7. method according to claim 6, it is characterised in that: step 1) described in forward primer and the nucleotide sequence of reverse primer such as shown in SEQIDNO:3 and SEQIDNO:4.
8. the application in preparing the medicine for diagnosing, prevent or treat Pseudomonas aeruginosa of the recombiant protein described in claim 1.
9. application according to claim 8, it is characterised in that described medicine is the test kit for diagnosing Pseudomonas aeruginosa.
10. application according to claim 8, it is characterised in that described medicine is the subunit vaccine for preventing or treat Pseudomonas aeruginosa.
CN201610117642.9A 2016-03-02 2016-03-02 Pseudomonas aeruginosa recombinant protein Vac11 and preparation method and application Active CN105753992B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610117642.9A CN105753992B (en) 2016-03-02 2016-03-02 Pseudomonas aeruginosa recombinant protein Vac11 and preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610117642.9A CN105753992B (en) 2016-03-02 2016-03-02 Pseudomonas aeruginosa recombinant protein Vac11 and preparation method and application

Publications (2)

Publication Number Publication Date
CN105753992A true CN105753992A (en) 2016-07-13
CN105753992B CN105753992B (en) 2019-11-29

Family

ID=56331566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610117642.9A Active CN105753992B (en) 2016-03-02 2016-03-02 Pseudomonas aeruginosa recombinant protein Vac11 and preparation method and application

Country Status (1)

Country Link
CN (1) CN105753992B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109293749A (en) * 2018-11-20 2019-02-01 重庆艾力彼生物科技有限公司 A kind of pseudomonas aeruginosa vaccine recombinant protein rExoU and preparation method thereof
CN109293750A (en) * 2018-11-20 2019-02-01 重庆艾力彼生物科技有限公司 A kind of pseudomonas aeruginosa vaccine recombinant protein SBP and preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103695508A (en) * 2013-12-09 2014-04-02 重庆原伦生物科技有限公司 Fermentation and purification technologies of staphylococcus aureus HI recombinant protein
CN104189898A (en) * 2014-06-27 2014-12-10 四川大学 Pseudomonas aeruginosa vaccine and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103695508A (en) * 2013-12-09 2014-04-02 重庆原伦生物科技有限公司 Fermentation and purification technologies of staphylococcus aureus HI recombinant protein
CN104189898A (en) * 2014-06-27 2014-12-10 四川大学 Pseudomonas aeruginosa vaccine and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIJOON LEE 等: "Cell-Wall Remodeling by the Zinc-Protease AmpDh3 from Pseudomonas aeruginosa", 《J AM CHEM SOC.》 *
NCBI: "MULTISPECIES: protein AmpDh3 [Pseudomonas]", 《GENBANK》 *
侯伟伟 等: "AmpCβ-内酰胺酶调控基因ampD的研究进展", 《检验医学》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109293749A (en) * 2018-11-20 2019-02-01 重庆艾力彼生物科技有限公司 A kind of pseudomonas aeruginosa vaccine recombinant protein rExoU and preparation method thereof
CN109293750A (en) * 2018-11-20 2019-02-01 重庆艾力彼生物科技有限公司 A kind of pseudomonas aeruginosa vaccine recombinant protein SBP and preparation method and application
CN109293749B (en) * 2018-11-20 2021-08-24 重庆艾力彼生物科技有限公司 Pseudomonas aeruginosa vaccine recombinant protein rExoU and preparation method thereof

Also Published As

Publication number Publication date
CN105753992B (en) 2019-11-29

Similar Documents

Publication Publication Date Title
CN104593397B (en) A kind of enterotoxigenic escherichia coil polyvalent antigen gene order of optimization and its application in preventing post-weaning diarrhea
CN105169381B (en) A kind of helicobacter pylori multivalence epitope vaccine and preparation method thereof
CN104877019B (en) Acinetobacter bauamnnii assumes the albumen and preparation method and application of albumin A 1S_1523
CN104861049B (en) Acinetobacter bauamnnii 1A1S_1969 recombinant proteins and its preparation method and application
CN103275912B (en) Enterorrhagia Bacillus coil 0157: H7 multivalence fliC-hcpA-tir-eae recombinant bacterium and vaccine
CN102181457B (en) Clostridium difficile exotoxin B amino-terminal gene sequence with optimized codon and nucleic vaccine of clostridium difficile exotoxin B
CN109293749B (en) Pseudomonas aeruginosa vaccine recombinant protein rExoU and preparation method thereof
CN109293750B (en) Pseudomonas aeruginosa vaccine recombinant protein SBP and preparation method and application thereof
CN104861050B (en) Acinetobacter bauamnnii zinc relies on Gly-Lys-Ala-Phe-Val-Lys-Lys 1S_1610 albumen and its preparation method and application
CN102993308B (en) Methicillin-resistant staphylococcus aureus (MRSA) vaccine recombinant protein antigen HI2 and preparation method and application thereof
CN102127554B (en) Japanese encephalitis particle vaccine and preparation method and application thereof
CN102058881B (en) Gene recombinant vaccine for preventing enterovirus 71 infection and preparation method thereof
CN105753992A (en) Pseudomonas aeruginosa recombinant protein Vac11 as well as preparation method and application
CN105732778A (en) Pseudomonas aeruginosa recombinant protein OprL as well as preparation method and application thereof
CN104651376A (en) Application of acinetobacter baumannii membrane protein A1S_0851 as antigen
CN105126093A (en) Helicobacter pylori tetravalent adhesion multi-epitope vaccine and preparation method thereof
CN105732818B (en) A kind of pseudomonas aeruginosa recombinant protein POP and its preparation method and application
CN107936123A (en) A kind of transmissible gastro-enteritis virus fusion protein and its preparation method and application
CN102199611A (en) Clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and nucleic acid vaccine thereof
CN105732817B (en) A kind of pseudomonas aeruginosa recombinant protein Vac33 and preparation method and application
CN103087198B (en) MRSA (Methicillin Resistant Staphylococcus Aureus) vaccine recombinant protein antigen I1C and preparation method and application thereof
CN108410784B (en) Streptococcus suis delta CPS/SsnA-mSly (P353L) -SC19 engineering bacteria and application thereof in vaccines
CN102533629A (en) Preparation method of avian encephalomyelitis virus VP1 protein subunit vaccine
CN105754978A (en) Pseudomonas aeruginosa recombinant protein Vac14 as well as preparation method and application
CN105647894A (en) Purification method of pseudomonas aeruginosa vaccine recombinant protein Vac11

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230806

Address after: 611731 No. 99, Tianxin Road, high tech Zone, Chengdu, Sichuan

Patentee after: CHENGDU OLYMVAX BIOPHARMACEUTICAL Co.,Ltd.

Patentee after: THIRD MILITARY MEDICAL University

Address before: Chongqing city Shapingba street 400038 gaotanyan No. 30

Patentee before: THIRD MILITARY MEDICAL University